In 2018 KDK Scientific was established to assist in the management of over 100 independent imaging studies for large pharmaceutical companies.  The majority of this research has involved PET/CT imaging utilizing novel radiopharmaceuticals to study oncologic diseases (e.g. Breast cancer, Prostate cancer, etc.), Alzheimer’s Disease along with other dementias, as well as Cardiac disease. KDK Scientific has successfully completed first in-human studies and are familiar with Phase I- IV studies.  In addition to serving as the PI on imaging trials, KDK Scientific has completed the PET/CT imaging component on over 80 therapeutic drug trials used for the treatment of various cancers, neurological diseases, cardiac disease and others.